Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jeffrey Walsh and Daniel Lynch join bluebird bio

This article was originally published in Scrip

Executive Summary

Bluebird bio, a company developing innovative gene therapies for severe genetic disorders, has appointed Daniel Lynch to its board of directors and Jeffrey Walsh as chief operating officer. Mr Lynch's previous roles include serving as CEO and CFO at ImClone Systems., while Mr Walsh was previously chief business officer of Taligen Therapeutics, where he was involved in the sale of Taligen the company to Alexion Pharmaceuticals in January 2011.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC012972

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel